Mark Shapiro is the Vice President of Clinical Development at Clinipace.

My colleague Renee Hart, Vice President of Strategic Accounts, and I recently presented at the Phacilitate Oncology Leaders’ Forum held in Boston. Our presentation, “Reducing Operational and Logistical Challenges in Immunoncology Trials,” included information on the inherent challenges in operations and logistical management in immunotherapy trials based on our experience. We also offered strategies that have proven to be successful in trials managed by our operational teams across the globe.

Throughout the forum, I was amazed at how immunoncology therapy has become mainstream. The level of optimism for combination immune therapies—such as a therapeutic cancer vaccine with a checkpoint pathway inhibitor or immune co-stimulator—was impressive. Despite the challenges with these types of clinical trials, an incredible amount of progress has been made. Many panelists and speakers made bold claims that immune therapies may displace traditional chemotherapies as first-line treatment for many types of tumors.

IMG_1248L to R: Dr. Jeff Humphrey, President, Chief Medical Officer at Kwoya Hakko Kirin Pharma, Inc., myself and Renee Hart, Vice President of Strategic Accounts at Clinipace.

Overall, the Clinipace team thoroughly enjoyed speaking with representatives from local biotechs and larger pharma companies. We’re excited to see what the future holds for this particular field as well as for many of the companies we spoke to.

If you’re interested in learning more about immunoncology, please listen to our recent webcast and be on the lookout for an eBook in the upcoming weeks.